端粒酶活性检测联合癌胚抗原、CA19-9对良恶性胸水的鉴别诊断价值

目的 探讨端粒酶活性联合癌胚抗原(CEA)、CA19-9在鉴别良、恶性胸水中的价值.方法 入选58例胸水患者,用改良的端粒重复序列扩增-酶联免疫吸附试验法检测胸水中脱落细胞端粒酶活性,并测定胸水CEA、CA19-9.结果 恶性胸水中端粒酶活性检出阳性率为85.7%.恶性胸水患者中端粒酶活性、CEA、CA19-9测定结果均明显高于良性胸水患者(P＜0.01).联合端粒酶、CEA、CA19-9共同检测,则敏感性为0.971,特异性为1.000.结论 端粒酶在诊断恶性胸水和鉴别良、恶性胸水中具有重要的价值,联合CEA、CA19-9对良、恶性胸水鉴别诊断意义更大.

Diagnostic significance of telomerase activity combined with carcinoembryonic antigen and CA19-9 for differentiating benign and malignant pleural effussion

Objective To investigate the diagnostic significance of telomerase activity combined with carcinoembryonic antigen(CEA)and CA19-9 for differentiating benign and malignant pleural effussion.Methods Telomerase activity.CEA and CA19-9 in pleural effussion from 58 cases were detected by the technique of improved telomeric repeat amplification protocol-enzyme linked immunosorbent assay.Results The positive rate of telomerase activity in malignant pleural effussion was 85.7%.The telomerase activity,CEA and CA19-9 in malignant pleural effussion were significantly higher than those in benign pleural effussion(P＜0.01).The sensitivity and specificity of detecting telomerase activity combined with CEA and CA19-9 were 0.971 and 1.000,respectively.Conclusions Telomerase assay is useful in differentiating malignant and benign pleural effussion,and will be more significant if combined with CEA and CA19-9.